Effectiveness and mood conversion rate of short-term fluoxetine monotherapy in patients with rapid cycling bipolar II depression versus patients with nonrapid cycling bipolar II depression

Journal of Clinical Psychopharmacology

Volumn 33, Issue 3, 2013, Pages 420-424

  Amsterdam, Jay D ^a   Luo, Lola ^b   Shults, Justine ^b  

^a The Science Center Philadelphia   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

bipolar disorder; depression; effectiveness; fluoxetine; randomized controlled trial

Indexed keywords

FLUOXETINE;

ADULT; AGED; ARTICLE; BIPOLAR II DISORDER; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HUMAN; HYPOMANIA; MAJOR CLINICAL STUDY; MALE; MANIA; MONOTHERAPY; MOOD CHANGE; NONRAPID CYCLING BIPOLAR II DEPRESSION; OUTCOME ASSESSMENT; OUTPATIENT; PRIORITY JOURNAL; RAPID CYCLING BIPOLAR II DEPRESSION; REMISSION; SHORT COURSE THERAPY; SUICIDE ATTEMPT; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BIPOLAR DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOXETINE; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877584344     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31828ea89e     Document Type: Article

References (30)

1. Maj M, Pirozzi R, Formicola AM, et al. Reliability and validity of four alternative definitions of rapid-cycling bipolar disorder. Am J Psychiatry. 1999; 156: 1421-1424.
2. Goldberg J, Ghaemi SN. Benefits and limitations of antidepressants and traditional mood stabilizers for treatment of bipolar depression. Bipolar Disord. 2005; 7(suppl): 3-12.
3. Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry. 2006; 163: 232-239.
4. Koukopoulos A, Sani G, Koukopoulos AE, et al. Duration and stability of the rapid-cycling course: a long-term personal follow-up of 109 patients. J Affect Disord. 2003; 73(1-2): 75-85.
5. Wehr TA, Sack DA, Rosenthal NE, et al. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry. 1988; 145: 179-184.
6. Kupfer DJ, Chengappa KNR, Gelenberg AJ, et al. Citalopram as adjunctive therapy in bipolar depression. J Clin Psychiatry. 2001; 62: 985-990.
7. Parker G, Tully L, Olley A, et al. SSRIs as mood stabilizers for bipolar II disorder: a proof of concept study. J Affect Disord. 2006; 92: 205-214.
8. Amsterdam JD, Wang G, Shults J. Venlafaxine monotherapy of bipolar II major depressive episode in non-responders to prior lithium monotherapy: a cross-over study. Acta Psychiatr Scand. 2010; 121: 201-208.
9. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007; 356: 1711-1722.
10. Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry. 1994; 55: 391-393.
11. Schneck CD, Miklowitz DJ, Miyahara S, et al. The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BD. Am J Psychiatry. 2008; 165: 370-377.
12. Amsterdam JD, Wang CH, Schwarz M, et al. Initial therapy of rapid and non-rapid cycling patients with bipolar II major depressive episode. J Affect Disord. 2009; 112: 219-230.
13. Cohn JB, Collins G, Ashbrook E, et al. A comparison of fluoxetine, imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol. 1989; 4: 313-322.
14. Amsterdam JD, Garcia-Espana F, Fawcett J, et al. Efficacy and safety of fluoxetine in bipolar II major depressive episode. J Clin Psychopharmacol. 1998; 18: 435-440.
15. Amsterdam JD, Shults J. Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode. Low mood conversion rate during initial fluoxetine monotherapy of bipolar type II major depressive episode. J Clin Psychopharmacol. 2010; 30: 306-311.
16. Williams JBW. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988; 45: 742-747.
17. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition With Psychotic Screen (SCID-I/P W/PSY SCREEN). New York, NY: Biometrics Research, New York State Psychiatric Institute; 2001.
18. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry. 1978; 133: 429-435.
19. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC: US Department of Health, Education, and Welfare; 1976; 218-222.
20. Shults J, Ratcliffe SJ, Leonard M. Improved generalized estimating equation analysis via xtqls for quasi-least squares in Stata. The Stata Journal. 2007; 7: 147-166.
21. American Psychiatric Association. Practice guidelines for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002; 159(suppl): 1-50.
22. Bauer MS, Callahan AM, Jampala C, et al. Clinical practice guidelines for bipolar disorder from the Department of Veterans Affairs. J Clin Psychiatry. 1999; 60: 9-21.
23. Suppes T, Calabrese J, Mitchell P, et al. Algorithms for the treatment of bipolar manic-depressive illness. Psychopharmacol Bull. 1995; 31: 469-474.
24. Frances AJ, Kahn DA, Carpenter D, et al. The expert consensus guidelines for treating depression in bipolar disorder. J Clin Psychiatr. 1998; 59 (suppl 4): 73-79.
25. Sachs GS, Printz DJ, Kahn DA, et al. The Expert Consensus Guidelinesi: Medication Treatment of Bipolar Disorder 2000. A Postgraduate Medicine Special Report. White Plains, NY: The McGraw-Hill Companies, Inc; 2000.
26. Ghaemi SN, Klara JR, Ko JY, et al. Antidepressant treatment in bipolar versus unipolar depression. Am J Psychiatry. 2004; 161: 163-165.
27. Gao K, Kemp DE, Ganocy SJ, et al. Treatment-emergent mania/hypomania during antidepressant monotherapy in patients with rapid cycling bipolar disorder. Bipolar Disord. 2008; 10: 907-915.
28. Amsterdam JD, Shults J. Fluoxetine monotherapy for bipolar type II and bipolar NOS major depressionVa double-blind, placebo-substitution, continuation study. Int Clin Psychopharmacol. 2005; 20: 357-364.
29. Amsterdam JD, Shults J. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar type II disorderVa randomized, double-blind, placebo-substitution trial. Am J Psychiatry. 2010; 167: 792-800.
30. Amsterdam JD, Shults J, Brunswick DJ, et al. Short-term fluoxetine monotherapy for bipolar type II or bipolar NOS major depressionVlow manic switch rate. Bipolar Disord. 2004; 6: 75-81.